Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Harmony Biosciences Holdings, Inc. (HRMY) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
Harmony Biosciences (HRMY) Surges 6.7%: Is This an Indication of Further Gains?
Harmony Biosciences (HRMY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Harmony Biosciences Holdings, Inc. Being Investigated on Behalf of Harmony Biosciences Holdings, Inc. Investors. Contact Levi & Korsinsky For Details.
NEW YORK, NY / ACCESSWIRE / September 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
An Investigation Has Commenced on Behalf of Harmony Biosciences Holdings, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your HRMY Losses.
NEW YORK, NY / ACCESSWIRE / September 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
Harmony Biosciences (HRMY) Upgraded to Buy: Here's What You Should Know
Harmony Biosciences (HRMY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
HRMY vs. REGN: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or Regeneron (REGN). But which of these two stocks presents investors with the better value opportunity right now?
Shareholder Rights Advocates at Levi & Korsinsky Investigate Harmony Biosciences Holdings, Inc. (HRMY) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / September 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).
Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says
UBS initiated coverage on Harmony Biosciences Holdings Inc HRMY, a commercial-stage biopharmaceutical company focused on rare neurological disorders.
HRMY or REGN: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Regeneron (REGN). But which of these two stocks offers value investors a better bang for their buck right now?
Is Harmony Biosciences (HRMY) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Harmony Biosciences: Unnoticed Melodies Of Portfolio Growth And Pipeline Potential
Harmony Biosciences' main product, WAKIX, drives significant revenue growth, with expansion potential in treating narcolepsy and other conditions, despite past controversies. The company's strategic acquisitions, including Zynerba and Epygenix, aim to diversify its portfolio, reducing reliance on WAKIX and boosting long-term growth prospects. Harmony's financial health is strong, with substantial cash reserves and high margins, allowing continued investment in research and development.
